Tarsus Pharmaceuticals Ownership
| TARS Stock | USD 33.52 0.10 0.30% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Tarsus |
Tarsus Stock Ownership Analysis
About 91.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.28. Tarsus Pharmaceuticals recorded a loss per share of 4.75. The entity had not issued any dividends in recent years. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Tarsus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people. To find out more about Tarsus Pharmaceuticals contact the company at 949 409 1801 or learn more at https://www.tarsusrx.com.Besides selling stocks to institutional investors, Tarsus Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Tarsus Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Tarsus Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Tarsus Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Tarsus Pharmaceuticals Insider Trades History
About 9.0% of Tarsus Pharmaceuticals are currently held by insiders. Unlike Tarsus Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Tarsus Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Tarsus Pharmaceuticals' insider trades
Tarsus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tarsus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tarsus Pharmaceuticals backward and forwards among themselves. Tarsus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Tarsus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Healthcare Of Ontario Pension Plan Trust Fund | 2024-03-31 | 898 K | Polygon Management Ltd | 2023-12-31 | 800 K | Ensign Peak Advisors Inc | 2024-03-31 | 727.9 K | State Street Corporation | 2024-03-31 | 717.1 K | Ikarian Capital, Llc | 2024-03-31 | 710.3 K | Geode Capital Management, Llc | 2024-03-31 | 629.7 K | Artisan Partners Limited Partnership | 2024-03-31 | 627.4 K | Vivo Capital, Llc | 2024-03-31 | 565.5 K | Dimensional Fund Advisors, Inc. | 2024-03-31 | 424.8 K | Rtw Investments, Llc | 2024-03-31 | 3.3 M | Blackrock Inc | 2024-03-31 | 2.7 M |
Tarsus Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tarsus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tarsus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tarsus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tarsus Pharmaceuticals Corporate Filings
8K | 8th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 26th of April 2024 Other Reports | ViewVerify | |
F4 | 19th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 1st of March 2024 Other Reports | ViewVerify |
Pair Trading with Tarsus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tarsus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tarsus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Tarsus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tarsus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tarsus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tarsus Pharmaceuticals to buy it.
The correlation of Tarsus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tarsus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tarsus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tarsus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.